Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints. The study will randomise 450 children to 3 groups: group A will receive measles containing vaccine (MCV) at 6 and 12 months ; group B at 9 and 18 months; Group C at 6 and 18 months.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5 months
Maximum Age: 6 months
Healthy Volunteers: t
View:
⁃ Aged 6 months (23 - 28 weeks) at time of screening
• Received all previous vaccines as per country Expanded Programme of Immunization (EPI) schedule, verified by child health card
• Parents/caretakers willing to give informed consent for their and their children's participation and stay in the geographical area where the study would be conducted
Locations
Other Locations
Uganda
Makarere University - Johns Hopkins University Collaboration
RECRUITING
Kampala
Contact Information
Primary
Oxford Vaccine Group
info@ovg.ox.ac.uk
01865 611400
Time Frame
Start Date: 2023-11-15
Estimated Completion Date: 2026-05-10
Participants
Target number of participants: 450
Treatments
Experimental: Group A: 6 and 12 months
Early Prime-Boost schedule: Measles vaccines given at 6 and 12 months of age
Experimental: Group B: 9 and 18 months (standard schedule)
Standard schedule: Measles vaccines given at 9 and 18 months of age
Experimental: Group C: 6 and 18 months
Early Prime schedule: Measles vaccines given at 6 and 18 months of age
Related Therapeutic Areas
Sponsors
Leads: University of Oxford
Collaborators: St George's, University of London, MU-JHU CARE